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nitric oxide synthase in an ovalbumin-induced
murine model of asthma
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Background: Dianthus superbus has long been used as a herbal medicine in Asia and as an anti-inflammatory
agent. In this study, we evaluated the anti-inflammatory effects of Dianthus superbus fructus ethanolic extract (DSE)
on Th2-type cytokines, eosinophil infiltration, and other factors in an ovalbumin (OVA)-induced murine asthma
model. To study the possible mechanism of the anti-inflammatory effect of DSE, we also evaluated the expression
of inducible nitric oxide synthase (iNOS) in the respiratory tract.
Methods: Mice were sensitized on days 0 and 14 by intraperitoneal injection of OVA. On days 21, 22 and 23 after
initial sensitization, mice received an airway challenge with OVA for 1 h using an ultrasonic nebulizer. DSE was
applied 1 h prior to OVA challenge. Mice were administered DSE orally at doses of 100 mg/kg or 200 mg/kg once
daily from day 18 to 23. Bronchoalveolar lavage fluid (BALF) was collected 48 h after the final OVA challenge. Levels
of interleukin (IL)-4, IL-13 and eotaxin in BALF were measured using enzyme-linked immunosorbent assays
(ELISAs). Lung tissue sections were stained with hematoxylin and eosin for assessment of cell infiltration and
mucus production with periodic acid shift staining, in conjunction with ELISA and western blot analyses for
iNOS expression.
Results: DSE significantly reduced the levels of IL-4, IL-13, eotaxin, and immunoglobulin (Ig) E, number of
inflammatory cells in BALF, and inflammatory cell infiltration and mucus production in the respiratory tract. DSE also
attenuated the overexpression of iNOS protein induced by OVA challenge.
Conclusion: Our results suggest that DSE effectively protects against allergic airway inflammation by
downregulating of iNOS expression and that DSE has potential as a therapeutic agent for allergic asthma.
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The prevalence of allergic asthma has increased mark-
edly in recent decades and has become an important
problem [1]. Allergic asthma is caused mainly by aller-
gens such as house dust, inhalants, foods, drugs, and
animal dander and its symptoms include wheez-
ing, coughing, tightness of the chest, and breathlessness
[2-4]. These symptoms results from bronchoconstriction* Correspondence: hkshin@kiom.re.kr
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reproduction in any medium, provided the orand bronchial mucosal thickening caused by eosinophilic
airway inflammation, airway remodeling, and excessive
mucus production. Allergic asthma is regarded as a
chronic inflammatory disease of the airway characterized
by airway inflammation and is mucus hypersecretion [5].
Airway inflammation in allergic asthma is under the
control of complex regulatory mechanisms involving the
releasing of T helper type 2 (Th2) cytokines, chemokines
and other signaling molecules, including nitric oxide
(NO) [5,6]. Under asthmatic condition, allergens pro-
cessed by antigen-presenting cells induce the activation
of Th2 cells, which release various cytokines, includingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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allergic response by increasing inflammatory cell infiltra-
tion into the airway and immunoglobulin (Ig)E secretion,
and by stimulating mucus hypersecretion [7,8]. NO plays
a crucial role in the pathogenesis of airway inflammation
in allergic asthma. NO is synthesized from L-arginine by
NO synthase (NOS), which exists in three isoforms:
neuronal NOS (nNOS), endothelial NOS (eNOS), and
inducible NOS (iNOS) [6]. Both nNOS and eNOS are
considered constitutive, and are involved in vasodilation
and bronchodilation [9]. iNOS seems to be involved
mainly in immunomodulation [6]. iNOS is stimulated by
many proinflammatory cytokines, and is responsible for
prolonged production of higher concentration of NO
[10]. iNOS production increases in asthmatic tissues and
several types of inflammatory cells [11]. Recent studies
have also shown that reducing iNOS expression attenu-
ates the asthmatic response in the respiratory tract in
various asthma models [10,12,13].
Currently, the standard medication for allergic asthma
comprises combined therapy including inhaled corticos-
teroids, leukotriene receptor antagonists, and others
[14]. However, these drugs produce side effects and do
not treat many asthmatic individuals consistently [15].
There is a pressing need for new agents for treating al-
lergic asthma, and herbal remedies are attracting in-
creasing attention as potential agents for this condition.
Many herbal remedies have shown protective effects in
experimentally induced allergic asthma models [16].
Dianthus superbus has long been used as a herbal
medicine in Asia and as an anti-inflammatory agent in
the treatment of urinary infections, carbuncles, and car-
cinoma of the esophagus [17,18]. A previous study
reported on the antioxidant and cytotoxic activities
of D. superbus fructus ethanolic extract (DSE) [19].
However, the effects of DSE have not been reported
in a murine model of allergic asthma. The aim of this study
was to investigate the effects of DSE on airway inflamma-




The dried fructus of D. superbus (300 g) were extracted
three times by sonication for 1 h with 3 L of 70% etha-
nol. The extracted solution was filtered through filter
paper and evaporated to dryness (56.89 g). The yield of
ethanolic extract obtained was 18.96%.
Animal
Specific pathogen-free female BALB/c mice (7 weeks
old) were purchased from the Orient Co. (Seoul, Korea)
and used after 1 week of quarantine and acclimatization.
The mice were allowed sterilized tap water and standardrodent chow. All experimental procedures were ap-
proved by Korea Institute of Oriental Medicine Institu-
tional Animal Care and Use Committee. This study was
performed in compliance with the National Institutes of
Health Guidelines for the care and use of laboratory ani-
mals and Korean national animal welfare law.
OVA-induced allergic asthma
OVA sensitization and airway challenge were performed
as described previously [5]. In brief, mice were sensitized
on days 0 and 14 by intraperitoneal injection of 20 μg
OVA emulsified in 2 mg aluminum hydroxide in 200 μL
PBS buffer (pH 7.4). On days 21, 22 and 23 after initial
sensitization, mice received an airway challenge with
OVA (1%, w/v, in PBS) for 1 h using an ultrasonic
nebulizer (NE-U12; Omron Corp., Tokyo, Japan). DSE
was dissolved in PBS and was prepared fresh daily before
each treatment. DSE was administered by gavage to mice
at doses of 100 mg/kg or 200 mg/kg once daily from day
18 to 23. Negative and positive control mice were orally
administered PBS or montelukast (30 mg/kg in PBS), re-
spectively. Montelukast was developed as a cysteinyl leu-
kotriene (cys-LT)-1 receptor antagonist [20] and was
introduced into the market after successful clinical
evaluation in patients with aspirin-sensitive asthma, noc-
turnal exacerbation of asthma, and allergic asthma [21].
Following OVA challenge, bronchoalveolar lavage fluid
(BALF) samples were obtained from the mice and pro-
cessed, and inflammatory cells were counted as
described previously [5]. In brief, mice were sacrificed by
intraperitoneal injection of pentobarbital (50 mg/kg;
Hanlim Pharm. Co., Seoul, Korea) 48 h after the last
challenge, and a tracheostomy was performed. To obtain
BALF, ice-cold PBS (0.5 mL) was infused into the lung
and withdrawn via tracheal cannulation three times
(total volume 1.5 mL). Total inflammatory cell numbers
were assessed by counting cells in at least five squares of
a hemocytometer after exclusion of dead cells by Trypan
blue staining. To determine differential cell counts, 100
μL of BALF was centrifuged onto slides using a Cytospin
(Hanil Science Industrial, Seoul, Korea) (200 g, 4°C,
10 min). The slides were dried, and the cells were
fixed and stained using Diff-QuikW staining reagent
(B4132-1A; IMEB Inc., Deerfield, IL), according to the
manufacturer’s instructions. The supernatant obtained
from BALF was stored at −70°C for biochemical
analysis.
Measurement of the levels of cytokines, chemokine,
and IgE
The levels of IL-4, IL-13, and eotaxin in BALF were
measured using enzyme-linked immunosorbent assay
(ELISA) kits (BioSource International, Camarillo, CA)
according to the manufacturer’s protocols. The levels of
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ELISA. Microtiter plates were coated with anti-IgE anti-
bodies (anti-mouse IgE; 10 g/mL; Serotec, Oxford, UK)
in PBS-Tween 20, and incubated with BALF or plasma
sample. The plates were then washed four times, and
200 μL of o-phenylenediamine dihydrochloride (Sigma-
Aldrich, St. Louis, MO) was added to each well. The
plates were incubated for 10 min in the dark and the ab-
sorbance was then measured at 450 nm.
Immunoblotting
Equal amounts of total lung protein (30 μg) were heated
at 100°C for 5 min, loaded onto 8% SDS-PAGE gels, and
electrophoresed. The proteins were then transferred to a
nitrocellulose membrane (at 100 V for 2 h). The mem-
brane was blocked for 1 h with Tris-buffered saline con-
taining 0.05% Tween-20 (TBST) plus 5% skim milk. It
was incubated with anti-iNOS (1:1000 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA) and anti-β-actin
(1:1000 dilution; Cell Signaling Technology, Danvers,
MA) overnight at 4°C. The membrane was washed three
times with TBST and then incubated with a horseradish
peroxidase (HRP)-conjugated secondary antibody (1:3000
dilution; Jackson ImmunoResearch, West Grove, PA) for
1 h at room temperature. The membrane was again
washed three times with TBST and developed using
an enhanced chemiluminescence kit (ECL; Amersham
Pharmacia Biotech, Uppsala, Sweden). For quantitative
analysis, densitometric band values were determined
using Chemi-Doc (Bio-Rad, Hercules, CA, USA).
Histology
After BALF samples were obtained, lung tissue was fixed
in 10% (v/v) neutral buffered formalin. Tissues were em-
bedded in paraffin, sectioned at 4 μm thickness, and
stained with H&E solution (hematoxylin, Sigma MHS-16,
and eosin, Sigma HT110-1-32) and periodic acid−Schiff
(PAS) (IMEB Inc., San Marcos, CA) to estimate inflamma-
tion and mucus production, respectively.
Measurement of NO and prostaglandin E2 (PGE2)
production in RAW 264.7 cells
The murine macrophage RAW 264.7 cell line was
obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA). The cells were cultured in
Dulbecco’s modified Eagle’s medium (Gibco Inc., Grand
Island, NY, USA) supplemented with 5.5% heat-
inactivated fetal bovine serum (Gibco Inc.), penicillin
(100 U/mL), and streptomycin (100 μg/mL) in a 5% CO2
incubator at 37°C. RAW 264.7 cells were plated at a
density of 2.5 х 105 cells/well in 48-well plates and incu-
bated overnight. Cells were treated with lipopolysacchar-
ide (LPS, 1 μg/mL) in the presence or absence of various
concentrations of DSE. After incubation for 18 h,supernatants were analyzed for the levels of NO (Griess
Reagent System, Promega Corp., Madison, WI, USA)
and PGE2 (Cayman Chemical Co., Ann Arbor, MI, USA)
according to the manufacturers’ protocols.Image capture and photomicrography
Photomicrographs were obtained using a Photometric
Quantix digital camera running a Windows program,
and montages were assembled in Adobe Photoshop 7.0.
Images were croppedand corrected for brightness and
contrast, but were not otherwise manipulated.Statistical analysis
Data are expressed as means ± standard error of the
mean (SEM). Statistical significance was determined
using analysis of variance (ANOVA) followed by a
multiple comparison test with Bonferroni adjustment.
P values < 0.05 or <0.01 were considered significant.Results
Suppression of OVA-induced eosinophilia in BALF
OVA-induced mice had significantly more eosinophils,
macrophages, neutrophils, and lymphocytes in BALF
compared with the negative control mice (Figure 1).
Montelukast-treated mice had significantly fewer
inflammatory cells than OVA-induced mice. Similarly,
DSE-treated mice had significantly fewer inflammatory
cells, particularly eosinophils, compared with OVA-
induced mice.Reduced levels of IL-4, IL-13, and eotaxin in BALF
The levels of IL-4 (74.3 ± 3.1 pg/mL, P < 0.01) and IL-13
(37.0 ± 1.9 pg/mL, P < 0.01) in BALF were significantly
higher in OVA-induced mice compared with the negative
controls. By contrast, montelukast-treated mice had sig-
nificantly lower levels of IL-4 (44.4 ± 6.6 pg/mL, P < 0.01)
and IL-13 (22.4 ± 0.9 pg/mL, P < 0.01) in BALF compared
with OVA-induced mice. DSE-treated mice had signifi-
cantly lower levels of IL-4 (52.6 ± 2.8 pg/mL in the 100
mg/kg DSE group, P < 0.01; 52.7 ± 4.2 pg/mL in the
200 mg/kg DSE group, P < 0.01) and IL-13 (28.9 ±
2.5 pg/mL in the 100 mg/kg DSE group, P < 0.05; 21.0 ±
2.1 pg/mL in the 200 mg/kg DSE group, P < 0.01) com-
pared with OVA-induced mice. The level of eotaxin
was also higher in OVA-induced mice (36.3 ± 1.5 pg/mL,
P < 0.01) compared with the negative controls. Similar to
the results for IL-4 and IL-5, eotaxin levels were lower
in mice treated with montelukast (28.1 ± 1.4 pg/mL,
P < 0.01) or DSE (28.8 ± 1.6 pg/mL in the 100 mg/kg
DSE group, P < 0.01; 29.9 ± 2.3 pg/mL in the 200 mg/kg
DSE group, P < 0.05) compared with the OVA-induced
mice. These results are shown in Figure 2.
Figure 2 DSE reduces the levels of IL-4, IL-5, and eotaxin in bronchoalveolar lavage fluid (BALF) of mice 48 h after the final OVA
challenge. OVA-induced mice had significantly higher levels of IL-4, IL-5, and eotaxin in BALF. DSE-treated mice had significantly lower levels of
IL-4, IL-5, and eotaxin compared with OVA-induced mice. NC, normal control mice treated with PBS only; OVA, OVA-sensitized/induced mice;
Mon, montelukast (30 mg/kg) + OVA-sensitized/induced mice; DSE-100, DSE (100 mg/kg) + OVA-sensitized/induced mice; DSE-200, DSE
(200 mg/kg) + OVA-sensitized/induced mice. Values are expressed as mean ± SEM (n = 6/group). ##Significantly different from NC, P < 0.01;
*,**significantly different from OVA, P < 0.05 and < 0.01, respectively.
Figure 1 DSE inhibits the recruitment of inflammatory cells in bronchoalveolar lavage fluid (BALF) of mice 48 h after the final OVA
challenge. Cells were isolated by centrifugation and stained with Diff-QuikW stain reagent. Cell numbers were counted using a light microscope by
counting cells in at least five squares of a hemocytometer after excluding dead cells using Trypan blue. NC, normal control mice treated with PBS only;
OVA, OVA-sensitized/induced mice; Mon, montelukast (30 mg/kg) + OVA-sensitized/induced mice; DSE-100, DSE (100 mg/kg) + OVA-sensitized/
induced mice; DSE-200, DSE (200 mg/kg) + OVA-sensitized/induced mice. Values are expressed as mean ± SEM (n = 6/group). ##Significantly different
from NC, P < 0.01; **significantly different from OVA, P < 0.01.
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Table 1 The levels of total IgE in BALF and plasma
Groups BALF (pg/mL) Plasma (ng/mL)
NC 231.9 ± 96.99 0.4 ± 0.33
OVA 3117.5 ± 999.75## 17.6 ± 4.31##
Mon 1677.9 ± 513.30** 10.8 ± 3.30*
DSE-100 1651.9 ± 501.03** 10.0 ± 4.80**
DSE-200 2057.4 ± 465.84* 15.5 ± 3.43
NC; normal control mice treated with PBS only; OVA; OVA-sensitized/
challenged mice; Mon; montelukast (30 mg/kg) + OVA-sensitized/challenged
mice; DSE-100; DSE (100 mg/kg) + OVA-sensitized/challenged mice; DSE-200;
DSE (200 mg/kg) + OVA-sensitized/challenged mice.
##Significantly different from NC, P < 0.01.
*,**significantly different from OVA, P < 0.05 and < 0.01, respectively.
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As shown in Table 1, the level of total IgE in BALF
was much higher in OVA-induced mice than in the
negative controls, and was significantly lower in
montelukast-treated mice compared with OVA-induced
mice. The total IgE level in BALF was significantly
lower in mice treated with DSE at 100 or 200 mg/kg
compared with OVA-induced mice. As observed for
IgE level in BALF, the level of total IgE in plasma was
significantly lower in mice treated with 100 mg/kg
DSE or with montelukast compared with OVA-inducedFigure 3 DSE inhibits the recruitment of inflammatory cells to lung ti
Histological examination of lung tissue with H&E stain (magnification x200)
sections. NC, normal control mice treated PBS only; OVA, OVA-sensitized/in
induced mice; DSE-100, DSE (100 mg/kg) + OVA-sensitized/induced mice; D
Values are expressed as mean ± SEM (n = 6/group). ##Significantly different
P < 0.01.mice. The total IgE level in plasma was nonsignifi-
cantly lower in 200 mg/kg DSE-treated mice compared
with OVA-induced mice.
Attenuation of inflammatory cell infiltration and mucus
production in lung tissue from OVA-induced mice
We observed a marked infiltration of inflammatory
cells into the peribronchiolar and perivascular lesions
in lung tissues sections from OVA-induced mice com-
pared with the negative control mice (Figure 3A).
Most infiltrated inflammatory cells were eosinophils.
By contrast, DSE-treated mice exhibited less infiltration
of inflammatory cells into the periobronchiolar and
perivascular lesions compared with the OVA-induced
mice. Quantitative analysis of inflammation showed
that DSE-treated mice had a significantly lower inflam-
mation index compared with the OVA-induced mice
(Figure 3B).
Lung sections from OVA-induced mice stained with
PAS exhibited overproduction of mucus and goblet cell
hyperplasia (Figure 4A). Sections from montelukast-
treated mice showed mild mucus production and goblet
cell hyperplasia in the bronchial airway compared with
OVA-induced mice. Quantitative analysis showed thatssue of mice 48 h after the final OVA challenge. (A)
. (B) Quantitative analysis of inflammatory cell infiltration in lung
duced mice; Mon, montelukast (30 mg/kg) + OVA-sensitized/
SE-200, DSE (200 mg/kg) + OVA-sensitized/induced mice.
from NC, P < 0.01; **Significantly different from OVA,
Figure 4 DSE reduces mucus production in lung tissues of mice 48 h after the final OVA challenge. (A) Histological examination of mucus
secretion in lung tissue with periodic acid Schiff (PAS) (magnification x200). (B) Quantitative analysis of mucus production in lung sections. NC,
normal control mice treated with PBS only; OVA, OVA-sensitized/induced mice; Mon, montelukast (30 mg/kg) + OVA-sensitized/induced mice;
DSE-100, DSE (100 mg/kg) + OVA-sensitized/induced mice; DSE-200, DSE (200 mg/kg) + OVA-sensitized/induced mice. Values are expressed as
mean ± SEM (n = 6/group). ##Significantly different from NC, P < 0.01; **Significantly different from OVA, P < 0.01.
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production index compared with OVA-induced mice
(Figure 4B).
Reduction in iNOS expression in lung tissue from
OVA-induced mice
To identify the possible protective mechanism under-
lying the activity of DSE in airway inflammation, we
investigated the expression of iNOS protein in relation
to inflammation in lungs of OVA-induced mice. As
shown in Figure 5A and B, OVA-induced mice showed
significantly greater iNOS expression in the lung tissue
compared with the negative controls. DSE-treated mice
had significantly lower iNOS expression compared with
OVA-induced mice.
Suppression of NO and PGE2 production in RAW
264.7 cells
We measured the cytotoxic effect of DSE on RAW
264.7 cells, exposed to various concentrations ranging
from 20 to 200 μg/mL of the DSE for 24 h. Cell viabil-
ity was then measured using the CCK-8 assay. Non-
toxic concentrations were used for the subsequent
experiments. LPS significantly increased NO production
by RAW 264.7 cells (Figure 6A). By contrast, DSEsignificantly decreased NO production in dose depen-
dent manner compared with only LPS-stimulated cells.
In PGE2 production, DSE significantly reduced the
increased PGE2 production induced by LPS stimulation,
which was consistent with the results of NO production
(Figure 6B).Discussion
In this study, we evaluated the anti-inflammatory effects
of DSE in an OVA-induced murine asthma model and
investigated its possible mechanism of action. OVA-
induced mice showed eosinophilia, airway inflammation,
mucus hypersecretion, and elevated levels of IL-4, IL-13
and eotaxin in BALF. OVA-induced mice had signifi-
cantly greater expression of iNOS in the lung tissue. By
contrast, DSE-treated mice had fewer inflammatory cells,
in particular eosinophils, in BALF and lung tissue, and
lower levels of IL-4, IL-13, and eotaxin in BALF com-
pared with OVA-induced mice. Administration of DSE
also reduced the expression of iNOS protein in lung tis-
sue compared with OVA-induced mice. To our know-
ledge, this is the first study to show that DSE decreases
airway inflammation in OVA-induced allergic asthma by
reducing iNOS expression.
Figure 5 DSE reduces the expression of iNOS protein in lung tissues of mice 48 h after the final OVA challenge. (A) iNOS protein
expression in the gel. (B) Relative units of iNOS protein expression. Relative units are expressed as the relative ratio of iNOS to β-actin. NC, normal
control mice treated with PBS only; OVA, OVA-sensitized/induced mice; Mon, montelukast (30 mg/kg) + OVA-sensitized/induced mice; DSE-100,
DSE (100 mg/kg) + OVA-sensitized/induced mice; DSE-200, DSE (200 mg/kg) + OVA-sensitized/induced mice. Values are expressed as mean ±
SEM (n = 6/group). ##Significantly different from NC, P < 0.01; **significantly different from OVA, P < 0.01.
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infiltration of inflammatory cells and excessive mucus pro-
duction into the airways [22]. Exposure to allergens
induces the activation of Th2 cells, which release Th2
cytokines such IL-4, IL-5, and IL-13. Elevated Th2 cyto-
kine levels stimulate infiltration of inflammatory cells into
the respiratory tract [5]. In ours study, administration of
DSE decreased both the numbers of inflammatory cells in
BALF and the production of Th2 cytokines. These results
were consistent with the results of the histopathological
examination. OVA-induced mice showed severe inflam-
mation in peribronchial lesions, whereas DSE-treated
mice showed milder inflammation compared with OVA-
induced mice. These results indicate that DSE effectively
protected the mice from OVA-induced airway inflamma-
tion. Administration of DSE also decreased the levels of
IgE in BALF and plasma and attenuated mucus hyperse-
cretion into the respiratory tract. Previous studies have
shown that Th2 cytokines increase IgE switching in B cells
and IgE binding to FcεRI on mast cells and basophils,
which accelerate the allergic response including the
production of proinflammatory mediators and mucus
secretion [5,7]. The results of our histopathological
study are consistent with these findings. Our results
suggest that DSE attenuates allergic response, includingairway inflammation and mucus hypersecretion, by redu-
cing Th2 cytokine release.
iNOS plays an important role in airway disease includ-
ing allergic asthma [11]. Airway inflammation is attribu-
ted to increased expression and activity of iNOS, which
increase NO production and consequently the numbers
of eosinophils in the airway and airway inflammation
[10,23]. Recent studies have shown that iNOS expression
is closely related to Th2 cytokines release in attenuating
the asthmatic response including airway constriction, in-
flammatory cell infiltration, and remodeling processes
[9,24,25]. In this study, the expression of iNOS was
much higher in OVA-induced mice compared with the
negative control mice and DSE significantly attenuated
the overexpression of iNOS induced by OVA in lung
tissue. These results were consistent with the changes
in Th2 cytokine production and histopathological examin-
ation of lung tissue. In addition, DSE significantly
reduced the increased NO production induced by
LPS stimulation in RAW 264.7 cells, which is con-
sistent with the results of western blot. Taken to-
gether, these results suggest that the reduction in
iNOS expression is one possible mechanism to which
DSE attenuates airway inflammation in experimentally
induced allergic asthma.
Figure 6 DSE reduces the increased NO and PGE2 production induced by LPS stimulation in RAW 264.7 cells. The production of NO (A)
and PGE2 (B) was measured in culture medium of cells treated with DSE (20–200 ug/mL) and then co-stimulated with LPS for 18 h. Values are
expressed as mean ± SEM. ##Significantly different from NC, P < 0.01; *,**significantly different from OVA, P < 0.05 and < 0.01, respectively.
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DSE is used traditionally for treatment of inflammatory
diseases in Korea and China. However, only limited in-
formation is available about pharmacological effects of
DSE. In particular, no data are available on the protect-
ive effect of DSE in allergic asthma. DSE was recently
reported to suppress IgE production in a human B cell
line and a murine model of peanut allergy [26]. Our
results show that DSE attenuates OVA-induced airway
inflammation in a murine model of asthma by downre-
gulation of iNOS expression. These findings suggest that
DSE may be useful as an adjuvant therapy for asthmatic
patients.
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